• Publications
  • Influence
Switching antipsychotic medications.
Compared with conventional antipsychotics, the so-called "atypical" antipsychotics promise improved side effect profiles and better control of the symptoms of schizophrenia. Therefore, most patientsExpand
  • 90
  • 7
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
OBJECTIVES This randomized, open-label trial was designed to help inform antipsychotic treatment policies. It compared the 1-year cost-effectiveness of initial treatment with olanzapine (OLZ) (n =Expand
  • 63
  • 6
Atypical antipsychotic drugs and long-term outcome in schizophrenia.
Long-term outcomes for patients with schizophrenia have been disappointing. The article discusses how the typical antipsychotics (clozapine and risperidone) as well as several agents that should beExpand
  • 154
  • 4
Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas
Excess mortality in persons with severe mental disorders (SMD) is a major public health challenge that warrants action. The number and scope of truly tested interventions in this area remain limited,Expand
  • 213
  • 3
  • PDF
Interventions for Weight Gain in Adults Treated With Novel Antipsychotics.
  • R. Aquila, M. Emanuel
  • Medicine
  • Primary care companion to the Journal of clinical…
  • 1 February 2000
BACKGROUND: Weight gain is a significant side effect associated with typical and atypical antipsychotic agents. It has the potential to add to the increased morbidity and mortality associated withExpand
  • 57
  • 2
Compliance and the rehabilitation alliance.
Expectations for the treatment of schizophrenia have historically been modest, with emphasis on eliminating positive symptoms and keeping patients out of the hospital. Noncompliance with traditionalExpand
  • 30
  • 1
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
BACKGROUND We assessed long-term metabolic and endocrine profiles of outpatients with schizophrenia participating in a one-year open-label extension study of monthly aripiprazole lauroxil (AL), aExpand
  • 2
  • 1
Management of weight gain in patients with schizophrenia.
  • R. Aquila
  • Medicine
  • The Journal of clinical psychiatry
  • 1 April 2002
Of the roughly 55% of the United States population that is considered overweight, half meet the criteria for obesity. Obesity is associated with serious health risks, but many clinicians graduateExpand
  • 36
Long-term considerations after switching antipsychotics.
The so-called "atypical" antipsychotics are rapidly becoming the de facto standard pharmacologic treatment of schizophrenia. This article reviews some common psychopharmacologic and psychologicalExpand
  • 24
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
Objective Safety and tolerability of long-term treatment with the long-acting antipsychotic aripiprazole lauroxil (AL) were evaluated in patients with schizophrenia. Methods This was anExpand
  • 11
  • PDF